Shenzhen Hepalink Releases 2025 Q3 Financial Report
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has released its unaudited Q3 financial report for 2025, covering the nine months ending September 30. The report, approved by the board, emphasizes transparency and regulatory compliance, which may enhance investor confidence. The latest analyst rating for its stock (HK:9989) is a Sell, with a price target of HK$4.31. The company operates in the pharmaceutical sector and is listed on the Hong Kong Stock Exchange, with a current market cap of HK$17.59B.
An update from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) is now available.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has released its unaudited third quarterly report for 2025, covering the nine months ending September 30, 2025. The report, prepared in accordance with PRC Accounting Standards, was approved by the board of directors, confirming the accuracy and completeness of the financial information. This announcement underscores the company’s commitment to transparency and regulatory compliance, potentially reinforcing investor confidence and maintaining its market position.
The most recent analyst rating on (HK:9989) stock is a Sell with a HK$4.31 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on the production and distribution of pharmaceutical products and services, with a market presence on the Hong Kong Stock Exchange.
Average Trading Volume: 1,658,250
Technical Sentiment Signal: Buy
Current Market Cap: HK$17.59B
Learn more about 9989 stock on TipRanks’ Stock Analysis page.
